Last reviewed · How we verify

NCT07241663: ROBIN

Surgery for Locally Unresectable Pancreatic Cancer

Recruiting now Last updated 26 November 2025
What this trial tests

trial testing Questionnaire in Locally Advanced Pancreatic Adenocarcinoma in 150 participants. Currently enrolling.

Timeline
1 January 2025
Primary endpoint
31 December 2026
31 December 2028

Quick facts

Lead sponsorAzienda Ospedaliera di Padova
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment150
Start date1 January 2025
Primary completion31 December 2026
Estimated completion31 December 2028
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

Azienda Ospedaliera di Padova — full company profile →

Who can join

18 and older, any sex, with Locally Advanced Pancreatic Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pancreatic cancer is a severe disease often diagnosed at an advanced stage, when surgery is not possible. New chemotherapy treatments can sometimes shrink the tumor and make surgery an option. This study aims to understand if surgery after such treatments can improve survival and quality of life in selected patients treated at expert centers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Questionnaire

Trials testing the same drug.

Other recruiting trials for Locally Advanced Pancreatic Adenocarcinoma

Currently open trials in the same condition.

Other Azienda Ospedaliera di Padova trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07241663.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing